MedDataX Logo

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

NCT ID: NCT06731842

Last Updated: 2024-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-15

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multi-modal PET tracer study with the aim of studying the time course of regional deposition of tau in brain of subjects with high risk of being carriers of autosomal dominant Alzheimer´s disease and sporadic early onset and late onset Alzheimer´s disease patient (EOAD, LOAD) in tertiary memory clinic cohort in relation to MRI brain changes, plasma biomarker levels and cognitive performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multi-PET /MRI studies , fluid biomarkers (CSF, plasma) analysis, neuropsychological testing is performed in subjects carriers and non-carriers of different APP, PS autosomal dominant AD mutatation. Both presymptomatic and symptomatic carriers and non-carriers are recruited (age range -30 to +15 years from first clinical symptoms). For comparison also a group of healthy eldersly as well as patients undergoing memory assessment with diagnosis of mild cognitive impairment (amyloid negative /amyloid positive) and diagnosis sporadic Alzheimer´s diases are recruited from Karolinska memory clinic and undergoing similar Multi-PET/MRI studies , fluid biomarker analysis, neuropsycholigal testing. The aim is to describe the evolution and spreading of tau in brain in Alzheimer continuum and compare with other pathological markers with aim of develop new diagnostic markers and therapeutic targets.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer´s Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAU PET and MRI investigation

Group Type OTHER

18F-RO948

Intervention Type OTHER

Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-RO948

Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

cancer and other serious disease
Minimum Eligible Age

30 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karolinska Institutet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Agneta Nordberg

MD PhD Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Agneta K NORDBERG, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Karolinska Institutet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karolinska institutet NVS

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-02649

Identifier Type: -

Identifier Source: org_study_id